BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viamet Pharmaceuticals Expands Phase 2 Clinical Program With Novel Antifungal Agent VT-1161


9/24/2013 9:48:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the expansion of the phase 2 clinical program for the novel antifungal agent VT-1161. The initial phase 2 study previously announced is designed to evaluate the safety and efficacy of VT-1161 in the oral treatment of acute vulvovaginal candidiasis (VVC). A second phase 2 clinical study has been initiated to evaluate the safety and efficacy of VT-1161 in the oral treatment of moderate to severe interdigital tinea pedis, commonly called athlete’s foot. Both studies are being conducted at leading clinical centers in the United States. VT-1161 has been shown in preclinical studies to potently inhibit, in a safe and selective manner, a wide range of fungal pathogens causing human disease. In previous phase 1 clinical studies, VT-1161 demonstrated good safety, tolerability and pharmacokinetics.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES